Stock GMAB GENMAB A/S
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Genmab A/S Nasdaq

Equities

GMAB

US3723032062

Market Closed - Nasdaq
Other stock markets
 21:00:00 21/05/2024 BST 		5-day change 1st Jan Change
29.15 USD -1.82% Intraday chart for Genmab A/S -1.29% -8.45%
05-15 Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation' MT
05-15 Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50% MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Genmab Completes Acquisition of ProfoundBio
BU
Genmab Completes Acquisition of ProfoundBio
GL
Transactions in Connection with Share Buy-back Program
GL
Legal Limbo: Genmab's Ofatumumab SPC Dilemma Heads To CJEU
AQ
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
BU
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
GL
Transactions in Connection with Share Buy-back Program
GL
Genmab A/S : has published its Articles of Association
PU
Genmab A/S : Articles of association dated May 07, 2024 – English
PU
Capital Increase in Genmab as a Result of Employee Warrant Exercise
GL
Transactions in Connection with Share Buy-back Program
GL
Genmab A/S : Investor Presentation - May 2024
PU
Genmab A/S : Interim Report for the First Quarter of 2024
PU
Genmab A/S : First Quarter 2024 Financial Results Presentation
PU
Genmab Announces Financial Results for the First Quarter of 2024
GL
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
GL
Transactions in Connection with Share Buy-back Program Genmab
GL
Transactions in Connection with Share Buy-back Program Genmab
GL
Transactions in Connection with Share Buy-back Program Genmab
AQ
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GMAB Stock
  4. GMAB Stock
  5. News Genmab A/S
  6. Press Releases